Small molecule c-Met kinase inhibitors: A review of recent patents

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 2, 2010, Pages 159-177

  Porter, John ^a  

^a UCB PHARMA   (Belgium)

Author keywords

C Met; Cancer; Hepatocyte growth factor; Hepatocyte growth factor receptor; Proliferation; Receptor tyrosine kinase; Signal transduction; Small molecule kinase inhibitor

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AM 7; AMG 208; ANTINEOPLASTIC AGENT; BMS 777607; C MET KINASE INHIBITOR; DIAMINOPYRIMIDINE DERIVATIVE; IMIDAZOPYRIMIDINE DERIVATIVE; IMIDAZOTRIAZINE DERIVATIVE; INCB 028060; JNJ 38877605; K 252A; METHYLISOTHIAZOLE; MK 2461; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PF 04217903; PHOSPHOTRANSFERASE INHIBITOR; PYRAZINE DERIVATIVE; PYRIDAZONE DERIVATIVE; PYRIDOPYRAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR; SGX 126; SGX 523; TRIAZOLOPYRIDAZINE DERIVATIVE; TRIAZOLOPYRIDINE DERIVATIVE; TRIAZOLOTRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CATALYSIS; CELL PROLIFERATION; CELL VIABILITY; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; EMBRYO DEVELOPMENT; ENZYME INHIBITION; EPITHELIUM CELL; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LIVER REGENERATION; MESENCHYME CELL; NONHUMAN; PATENT; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; WOUND HEALING;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 76149091189     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903514137     Document Type: Review

References (122)

1. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;2:296-313
2. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006;312:1175-1178
3. Gherardi E, Sandin S, Petoukhov MV, et al.. Structural basis of hepatocyte growth factor/scatter factor and MET signaling. Proc Natl Acad Sci USA 2006;103:4046-4051
4. Peruzzi B, Bottardo DP. Targeting the c-Met signaling pathway. Clin Cancer Res 2006;12:3657-3660
5. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Invest Drugs 2008;17:997-1011
6. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002;109:863-867
7. Birchmeier CBW, Gherardi E, Van De Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925
8. Seiwert TY, Jagadeeswaran R, Faoro L, et al.. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009;69:3021-3031
9. Bean J, Brennan C, Shih J-Y, et al.. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-20937
10. Smolen GA, Sordella R, Muir B, et al.. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006;103:2316-2321
11. Bachleitner-Hofmann T, Sun MY, Chen CT, et al.. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 2008;7:3499-3508
12. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discovery 2008;7:504-516
13. Jun HT, Sun J, Rex K, et al.. AMG 102, A fully human anti-hepatocyte growth factor/ scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13:6735-6742
14. Martens T, Schmidt N-O, Eckerich C, et al.. A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo . Clin Cancer Res 2006;12:6144-6152
15. Cui JJ. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert Opin Ther Patents 2007;17:1035-1045
16. Backes AC, Zech B, Felber B, et al.. Small molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type 1 inhibition. Expert Opin Drug Discov 2008;3:1409-1425
17. Backes AC, Zech B, Felber B, et al.. Small molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin Drug Discov 2008;3:1427-1449
18. Schiering N, Knapp S, Marconi M, et al.. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Nat Acad Sci USA 2003;100:12654-12699
19. Sattler M, Pride YB, Ma P, et al.. A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-5469
20. Berthou S, Aebersold DM, Schmidt LS, et al.. The Met kinase inhibitor SU-11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004;23:5387-5393
21. Smolen GA, Sordella R, Muir B, et al.. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Nat Acad Sci USA 2006;103:2316-2321
22. Christensen JG, Screck R, Burrows J, et al.. A selective small molecule inhibitor of c-Met kinase inhibits c-Met dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2009;63:7345-7355
23. Zou HY, Li Q, Lee JH, et al.. An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-4417
24. McTigue MA, Wickersham J, Grodsky N, et al.. Crytal structures of diverse inhibitors bound to c-Met kinase reveal multiple protein conformations [abstract 3183]. 99th Annual Meeting for American Association for Cancer Research (AACR); 12-16 April 2008; San Diego, USA
25. Bellon SF, Kaplan-Lefko P, Yang Y, et al.. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008;283:2675-2683
26. Dussault I, Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anti Cancer Agents Med Chem 2009;9:221-229
27. Amgen, Inc. Fused heterocyclic derivatives and methods of use. WO08008539; 2008
28. Romero K, Bauer D, Bellon SF, et al.. Medi 136 Triazolopyridazine derivatives as selective and orally bioavailable c-Met inhibitors[Medi 136]. 238th American Chemical Society (ACS) National Meeting; 16 August 2009; Washington, USA
29. Amgen, Inc. Nitrogen containing heterocyclyl ketones and methods of use. WO08103277; 2008
30. Amgen, Inc. Fused heterocyclic derivatives and methods of use. WO09091374; 2009
31. Albrecht BK, Harmange JC, Bauer D, et al.. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem 2008;51:2879-2882
32. AstraZeneca. Pyrazine derivatives. WO09007390; 2009
33. AstraZeneca. Pyridine and pyrazine derivatives. WO09053737; 2009
34. AstraZeneca. 2-Pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors. WO09024825; 2009
35. Bayer Schering Pharma Aktiengesellschaft. Dihydropyridinone derivatives useful as kinase inhibitors. WO08071451; 2008
36. Cephalon, Inc. Pyridopyrazines and derivatives thereof as Alk and c-Met inhibitors. WO07130468; 2007
37. Cephalon, Inc. and Pharmacopeia Drug Discovery, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as Alk and c-Met inhibitors. WO08051547; 2008
38. Chroma Therapeutics Ltd. Aminoheteroaryl compounds as for the treatment of diseases mediated by c-Met kinase activity. WO08053157; 2008
39. Merck Patent Gmbh. 2-(Heterocyclylbenzyl)pyridinazinone derivatives. WO08017361; 2008
40. Merck Patent Gmbh. Aryl ether pyridazinone derivatives. WO08145242; 2008
41. Merck Patent Gmbh. Pyridazinone derivatives. WO08145243; 2008
42. Merck Patent Gmbh. 2-Oxo-3-benzyloxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors. WO08148449; 2008
43. Merck Patent Gmbh. Pyrimidinyl pyridazinone derivatives. WO09007074; 2009
44. Merck Patent Gmbh. Pyridazinone derivatives. WO09006959; 2009
45. Merck Patent Gmbh. 6-Thioxo-pyridazine derivatives. WO09024221; 2009
46. Merck Patent Gmbh. Thiadiazinone derivatives. WO09030333; 2009
47. Merck Patent Gmbh. 2-Benzylpyridazinone derivatives as Met kinase inhibitors. WO09083076; 2009
48. Hoffmann-La Roche AG. Fused pyridines active as inhibitors of c-Met. WO09093049; 2009
49. Incyte Corp. Imidazotriazines and imidazopyrimidines as kinase inhibitors. WO08064157; 2008
50. Incyte Corp. Triazolotriazines as kinase inhibitors. US20080039457; 2008
51. Liu X, Koblish H, Wang Q, et al.. Discovery and characterization of INCB028060, a novel, potent and selective Met RTK inhibitor for cancer treatment [abstract 2577]. 99th Annual Meeting for American Association for Cancer Research (AACR); 12-16 April 2008; San Diego, USA
52. Janssen Pharmaceutica NV. Triazolopyridazines as kinase modulators. WO07075567; 2007
53. Perera T, Lavrijssen T, Janssens B, et al.. JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models [abstract 4837]. 99th Annual Meeting for American Association for Cancer Research (AACR); 12-16 April 2008; San Diego, USA
54. Merck & Co, Inc. Tyrosine kinase inhibitors. WO08008310; 2008
55. Merck & Co, Inc. Tyrosine kinase inhibitors. WO07002254; 2007
56. Merck & Co, Inc. Tyrosine kinase inhibitors. WO07002258; 2007
57. Camacho L, Moulder S, LoRusso P, et al.. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors . J Clin Oncol 2008;26:14657
58. Pan B-S, Chenard M, Davis L, et al.. In vitro and in vivo anti-tumor activities of a novel c-Met kinase inhibitor [abstract 2368]. 98th Annual Meeting for American Association for Cancer Research (AACR); 14-18 April 2007; Los Angeles, USA
59. Merck & Co, Inc. Tyrosine kinase inhibitors. WO07149427; 2007
60. Merck & Co, Inc. Tyrosine kinase inhibitors. WO07050309; 2007
61. Pfizer Products, Inc. Triazolopyridazine derivatives. WO07138472; 2007
62. Pfizer Products, Inc. Triazolopyrazine derivatives useful as anti-cancer agents. WO07132308; 2007
63. Zou H, Li Q, Joseph L, et al.. PF-04217903, a novel selective c-Met kinase inhibitor with potent antitumor and anti-angiogenic properties in vitro and in vivo [abstract 4841]. 99th Annual Meeting for American Association for Cancer Research (AACR); 12-16 April 2008; San Diego, USA
64. Timofeevski SL, McTigue MA, Ryan K, et al.. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 2009;48:5339-5349
65. Sanofi-Aventis. Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for the production thereof and application as medicaments and pharmaceutical compositions and novel use as Met inhibitors. WO09056692; 2009
66. Sanofi-Aventis. 6-Aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, methods for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as Met inhibitors. WO09087305; 2009
67. OSI Pharmaceuticals, Inc. Furo- and Thieno[3,2-c]pyridines. US20090197864; 2009
68. OSI Pharmaceuticals, Inc. 2-Aminopyridine kinase inhibitors. US20090197862; 2009
69. SGX Pharmaceuticals, Inc. Heterocyclic kinase modulators. US20090156594; 2009
70. SGX Pharmaceuticals, Inc. Pyrrolopyridine kinase modulators. WO08124849; 2008
71. SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators. WO08124850; 2008
72. Hirst G. Integration of fragment derived structure-based design into the discovery and development of selective kinase inhibitors for treatment of human cancers. XXth EFMC-ISMC; 1 September 2008; Vienna, Austria
73. Smithkline Beecham Corp. Novel compounds. WO08067119; 2008
74. Smithkline Beecham Corp. Novel compounds. WO08060866; 2008
75. Vertex Pharmaceuticals, Inc. Heterocyclic inhibitors of c-Met and uses thereof. WO08036272; 2008
76. Vertex Pharmaceuticals, Inc. Inhibitors of c-Met and uses thereof. WO07064797; 2007
77. Vertex Pharmaceuticals, Inc. c-Met kinase inhibitors. WO09045992; 2009
78. Vertex Pharmaceuticals, Inc. c-Met protein kinase inhibitors. WO07111904; 2007
79. Xcovery, Inc. Kinase inhibitor compounds. WO08088881; 2008
80. Angion Biomedica Corp. Modulators of hepatocyte growth factor/c-Met activity. WO07081978; 2007
81. Amgen, Inc. Substituted heterocycles and methods of use. WO08079294; 2008
82. Amgen, Inc. Substituted heterocycles and methods of use. WO08079291; 2008
83. Amgen, Inc. Bis-aryl amide derivatives and methods of use. WO08086014; 2008
84. Liu L, Siegmund A, Xi N, et al.. Discovery of a potent, selective and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5- (7-methoxyquinolin-4-yloxy) pyridin-2-yl)-5-methyl-3-oxo-2-phenyl- 2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem 2008;51:3688-3691
85. Teffera Y, Colletti AE, Harmange JC, et al.. Chemical reactivity of methoxy 4-O-aryl quinolines: identification of glutathione displacement products in vitro and in vivo. Chem Res Toxicol 2008;21:2216-2222
86. Amgen, Inc. Substituted heterocycles and methods of use.WO08079291; 2008
87. D'Angelo ND, Bellon SF, Booker SK, et al.. Design, synthesis, and biological evaluation of potent c-Met inhibitors. J Med Chem 2008;51:5766-5779
88. Array Biopharma, Inc. and Genentech, Inc. Pyrazolo-pyridines as tyrosine kinase inhibitors. WO09033084; 2009
89. Array Biopharma, Inc. and Genentech, Inc. Heterobicyclic pyrazole compounds and methods of use. WO07103308; 2007
90. Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use. WO08063202; 2008
91. Array Biopharma, Inc. and Genentech, Inc. Quinoline compounds and methods of use. WO07146824; 2007
92. Bayer Healthcare AG. Pyridone carboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders. WO08048375; 2008
93. Bayer Pharmaceuticals Corp. Pyrazolyl urea derivatives useful in the treatment of cancer. WO07059202; 2007
94. Bayer Pharmaceuticals Corp. Urea compounds useful in the treatment of cancer. WO07064872; 2007
95. Bristol-Myers Squibb Company. Met kinase inhibitors. WO07041379; 2007
96. Bristol-Myers Squibb Company. Met kinase inhibitors.WO07035428; 2007
97. Bristol-Myers Squibb Company. Met kinase inhibitors. US20070060613; 2007
98. Bristol-Myers Squibb Company. Pyrrolotriazine kinase inhibitors. US20070123534; 2007
99. Bristol-Myers Squibb Company. Pyridinone compounds. WO080058229; 2008
100. Bristol-Myers Squibb Company. 4-Pyridinone compounds and their use for cancer. WO0904417; 2009
101. Bristol-Myers Squibb Company. 4-Pyridinone compounds and their use for cancer. WO0904427; 2009
102. Schroeder GM, Chen X-T, Williams DK, et al.. Identification of pyrrolo[2,1-f][1,2,4] triazine-based inhibitors of Met kinase. Bioorg Med Chem Lett 2008;18:1945-1951
103. Cai Z-W, Wei D, Schroeder GM, et al.. Discovery of orally active pyrrolopyridineand aminopyridine-based Met kinase inhibitors. Bioorg Med Chem Lett 2008;18:3224-3229
104. Kim KS, Zhang L, Schmidt RJ, et al.. Discovery of pyrrolopyridine- pyridone based inhibitors of Met kinase:synthesis, x-ray crystallographic analysis and biological activities. J Med Chem 2008;51:5330-5341
105. Schroeder GM, An Y, Cai Z-W, et al.. Discovery of N-(4-(2-amino-3- chloropyridin-4-yloxy)-3-fluorophenyl)-4- ethoxy-1-(4-fluorophenyl)- 2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2009;52:1251-1254
106. Exelixis, Inc. c-Met modulators and methods of use. US20090170896; 2009
107. Eisai R&D Management Co Ltd. A pharmaceutical composition for treating eosphageal cancer. WO09077874; 2009
108. Eisai R&D Management Co Ltd. Novel pyridine derivative and pyrimidine derivative. WO07023768; 2007
109. Obaishi H, Nakagawa H, Yamaguchi A. E7050: a novel small molecule inhibitor of the c-Met and VEGFR-2 tyrosine kinases [abstract 4846]. 99th Annual Meeting for American Association for Cancer Research (AACR); 12-16 April 2008; San Diego, USA
110. Nakagawa T, Obaishi H, Yamaguchi A, et al.. E7050: a novel orally active c-Met and VEGFR-2 tyrosine kinase inhibitor exhibited potent antitumor effect and prolongation of survival in preclinical mice model [abstract 4845]. 99th Annual Meeting for American Association for Cancer Research (AACR); 12-16 April 2008; San Diego, USA
111. Glaxo Group Ltd. Novel compounds. WO08049855; 2008
112. Methylgene, Inc. Inhibitors of protein tyrosine kinase activity. WO09026717; 2009
113. Methylgene, Inc. Kinase inhibitors and use thereof. WO08046216; 2008
114. Methylgene, Inc. Inhibitors of protein tyrosine kinase activity. US20080004273; 2008
115. Claridge S, Raeppel F, Granger MC, et al.. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorg Med Chem Lett 2008;18:2793-2798
116. Raeppel S, Claridge S, Saavedra O, et al.. N-(3-fluoro-4- (2-arylthieno[3,2-b]pyridin-7-yloxy) phenyl)-2-oxo-3-phenylimidazolidine- 1-carboxamides:a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2009;19:1323-1328
117. Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treating cancer. WO09002806; 2009
118. Arqule, Inc. Compositions and methods for treatment of cancer. WO09002807; 2009
119. Laux I, Goldman J, Just RBK, et al.. phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib [abstract 3459]. 45th Annual Meeting of the American Society of Clinical Oncology (ASCO); 29 May - 2 June 2009; Orlando, USA
120. Porter J, Lumb S, Franklin RJ, et al.. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett 2009;19:2780-2784
121. Porter J, Lumb S, Lecomte F, et al.. Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase. Bioorg Med Chem Lett 2009;19:397-400
122. Liao JJ-L. Molecular recognition of protein kinase binding pockets for the design of potent and selective kinase inhibitors. J Med Chem 2007;50:409-424